Therefore, it seems that especially for patients with concomitant type 2 DM, treatment with SGLT-2 inhibitors may decrease the risk for subsequent AMI, while it might have no or minimal effect on the risk for other forms of CAD, mainly unstable angina. The gene discussed is SLC5A2; the disease is coronary artery disorder.